OBJECTIVES AND METHODS: Alternative splicing provides proteomic diversity that can have profound effects. The extent, pattern, and roles of alternative splicing in pancreatic cancer have not been systematically investigated. We have utilized a spliceoform-specific microarray and polymerase chain reaction to evaluate all known splice variants in human pancreatic cancer cell lines representing a spectrum of differentiation, from near-normal HPDE6 to Capan-1 and poorly differentiated MiaPaCa2 cells. Validation of altered spliceoforms was verified in primary cancer specimens and normal pancreatic ductal cells. In addition, expression of 92 spliceosomal genes was examined to better understand the mechanism for observed differences in mRNA splicing. RESULTS: A statistically significant reduction in alternative splicing was found in the pancreatic cancer cell lines compared with HPDE6 cells. Many splice variants identified in Capan-1 and MiaPaCa2 cells were observed in grades 3 and 4 tumors. Analysis of genes encoding spliceosomal proteins revealed that 28 of 92 genes had significantly decreased expression in cancer compared with normal pancreas. CONCLUSIONS: Pancreatic cancer has reduced alternative splicing diversity compared with normal pancreas. This is demonstrated in both cell lines and primary tumors, with the loss in splicing diversity correlated with relative reduction in expression of spliceosomal genes.
OBJECTIVES AND METHODS: Alternative splicing provides proteomic diversity that can have profound effects. The extent, pattern, and roles of alternative splicing in pancreatic cancer have not been systematically investigated. We have utilized a spliceoform-specific microarray and polymerase chain reaction to evaluate all known splice variants in humanpancreatic cancer cell lines representing a spectrum of differentiation, from near-normal HPDE6 to Capan-1 and poorly differentiated MiaPaCa2 cells. Validation of altered spliceoforms was verified in primary cancer specimens and normal pancreatic ductal cells. In addition, expression of 92 spliceosomal genes was examined to better understand the mechanism for observed differences in mRNA splicing. RESULTS: A statistically significant reduction in alternative splicing was found in the pancreatic cancer cell lines compared with HPDE6 cells. Many splice variants identified in Capan-1 and MiaPaCa2 cells were observed in grades 3 and 4 tumors. Analysis of genes encoding spliceosomal proteins revealed that 28 of 92 genes had significantly decreased expression in cancer compared with normal pancreas. CONCLUSIONS:Pancreatic cancer has reduced alternative splicing diversity compared with normal pancreas. This is demonstrated in both cell lines and primary tumors, with the loss in splicing diversity correlated with relative reduction in expression of spliceosomal genes.
Authors: Joanne M Yeakley; Jian-Bing Fan; Dennis Doucet; Lin Luo; Eliza Wickham; Zhen Ye; Mark S Chee; Xiang-Dong Fu Journal: Nat Biotechnol Date: 2002-04 Impact factor: 54.908
Authors: Richard E Green; Benjamin P Lewis; R Tyler Hillman; Marco Blanchette; Liana F Lareau; Aaron T Garnett; Donald C Rio; Steven E Brenner Journal: Bioinformatics Date: 2003 Impact factor: 6.937
Authors: Jun Wang; Laurent Dumartin; Andrea Mafficini; Pinar Ulug; Ajanthah Sangaralingam; Namaa Audi Alamiry; Tomasz P Radon; Roberto Salvia; Rita T Lawlor; Nicholas R Lemoine; Aldo Scarpa; Claude Chelala; Tatjana Crnogorac-Jurcevic Journal: Sci Rep Date: 2017-06-07 Impact factor: 4.379
Authors: Bruno Sainz; Raúl M Luque; Justo P Castaño; Emilia Alors-Perez; Ricardo Blázquez-Encinas; Sonia Alcalá; Cristina Viyuela-García; Sergio Pedraza-Arevalo; Vicente Herrero-Aguayo; Juan M Jiménez-Vacas; Andrea Mafficini; Marina E Sánchez-Frías; María T Cano; Fernando Abollo-Jiménez; Juan A Marín-Sanz; Pablo Cabezas-Sainz; Rita T Lawlor; Claudio Luchini; Laura Sánchez; Juan M Sánchez-Hidalgo; Sebastián Ventura; Laura Martin-Hijano; Manuel D Gahete; Aldo Scarpa; Álvaro Arjona-Sánchez; Alejandro Ibáñez-Costa Journal: J Exp Clin Cancer Res Date: 2021-12-02